Clinical trials: Breast Atypical Hyperplasia
Breast Neoplasms
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality…
- Trial name
- NCT00146536
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Dana-Farber Cancer Institute
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- DEEM (NCT01874184)
- Testing
- counseling intervention, behavioral dietary intervention, exercise intervention
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Atypical Ductal Hyperplasia
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
This research study is studying whether contrast enhanced mammography can predict if atypical ductal hyperplasia will progress to cancer. The device involved in this study is: -Contrast enhanced mammography
- Trial name
- NCT03505372
- Testing
- Contrast enhanced mammography
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer, Endometrial Hyperplasia With Atypia
Endometrial Changes in Breast Cancer Women.
This is a prospective observational multicentric study. The aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant…
- Conditions
- Endometrial Cancer, Endometrial Hyperplasia With Atypia, Breast Cancer, TAM
- Trial name
- NCT05717634
- Testing
- Hysteroscopy
- Where
- Italy
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Breast Cancer
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
The overall goal of this project is to develop an integrative system of breast cancer risk assessment based on epidemiologic and biologic risk variables, as well as to develop or refine risk biomarkers which may be useful in…
- Trial name
- NCT00291096
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia
Ruxolitinib for Premalignant Breast Disease
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for…
- Conditions
- Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
- Trial name
- TBCRC042 (NCT02928978)
- Testing
- Ruxolitinib
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Julie Nangia
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer
To assess the quantitative real time PCR results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.
- Trial name
- NCT00291122
- Testing
- celecoxib 400 mg BID
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Kansas
Breast Cancer
Women At Risk: The High Risk Breast Cancer Program
The purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. Data from this group will be collected and entered into a registry.
- Trial name
- WAR (NCT01034891)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- New York Presbyterian Hospital
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia
Molecular Breast Imaging in Women With Atypia and LCIS
We aim to determine if Molecular Breast Imaging (a new nuclear medicine technique developed at Mayo) can identify malignant breast lesions in women who have atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular…
- Conditions
- Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
- Trial name
- NCT00620087
- Testing
- Molecular Breast Imaging, Screening Mammography
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
The overall goal of this project is to determine if high dose vitamin D3 given to premenopausal women at high risk for development of breast cancer, who initially have insufficient levels of 25-hydroxy vitamin D (<30 ng/ml), will…
- Trial name
- NCT01166763
- Testing
- vitamin D3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Carol Fabian, MD
Atypical Ductal Breast Hyperplasia, Breast Cancer
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Chemoprevention is the use of certain drugs to keep cancer from forming. The use of atorvastatin (Lipitor) may prevent breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Breast Cancer, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Trial name
- NCT00637481
- Testing
- atorvastatin calcium, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
This randomized pilot clinical trial studies a nanoemulsion formulation of curcumin in reducing inflammatory changes in breast tissue in obese women at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ
- Trial name
- NCT01975363
- Testing
- curcumin, Biomarker analysis, Assessment of Dietary Intake
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve…
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05178498
- Testing
- Follow-Up, Physical Examination, Questionnaire Administration
- Where
- United States
- Volunteers
- 960 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Markers for Breast Cancer
This study will analyze blood samples to identify substances that are associated with the development of breast cancer. It will determine if: Women who are diagnosed with a benign breast condition that is related to a…
- Trial name
- NCT00339248
- Where
- United States
- Volunteers
- 2,632 people
- Sponsor
- National Cancer Institute (NCI)
Atypical Ductal Hyperplasia, Ductal Carcinoma in Situ
Excisional Vacuum-Assisted Breast Biopsy
The goal of this prospective cohort study is to evaluate the possibility of vacuum-assisted excisional biopsy (VAE) to completely remove the pathology in case of small lesions for Atypical Ductal Hyperplasia (ADH) and…
- Trial name
- NCT05932758
- Testing
- Vacuum-assisted excisional biopsy, Not excisional biopsy
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- European Institute of Oncology
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ
- Trial name
- NCT06184750
- Testing
- Biopsy Procedure, Biospecimen Collection, Mammography
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers.
- Conditions
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- Trial name
- NCT04496739
- Testing
- Cancer Educational Materials, Decision Aid, Interview
- Where
- 97 sites in United States, Guam
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
To examine nipple aspirate fluid for secretions that may be identified as a high risk indicator for development of breast cancer, and compare those to serum analysis.
- Trial name
- NCT00291083
- Where
- United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
- Conditions
- Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
- Trial name
- NCT04570956
- Testing
- Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic